Project Grant K01CA300651
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $200K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
- Federal Grant Award Summary Albert Einstein College of Medicine received a $680,121 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through March 31, 2031. This award supports fundamental research to understand the immunoevasion mechanisms employed by precancerous stem cells in basal-like breast cancer (BLBC), with the goal of developing immunoprevention strategies to intercept progression to aggressive...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $692,197 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) for the period May 1, 2026 through April 30, 2031. The award funds research and development of MTAP (Methylthioadenosine Phosphorylase) transition state analog inhibitors designed to enable synthetic-lethal cancer therapy approaches. The project delivers novel, highly specific MTAP inhibitor compounds and...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $442,816 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded April 2, 2026, with completion targeted for March 31, 2027. This award funds research interrogating erythroid differentiation and the BCL-XL axis in TP53-mutated acute myeloid leukemia (AML). The project addresses a critical clinical gap by investigating how TP53-mutated AML patients...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2028. The award supports research to decipher mechanisms of resistance to anti-TROP2 (tumor-associated glycoprotein 2) antibody-drug conjugates, specifically sacituzumab govitecan (SG), which is currently approved for treating advanced...
- Federal Grant Award Summary The National Cancer Institute awarded a $168,000 Project Grant to Albert Einstein College of Medicine under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2028. The grant supports research to elucidate the mechanisms of pancreatic ductal adenocarcinoma (PDAC) dormancy and minimal residual disease (MRD), with particular focus on identifying and validating therapeutic targets. The research will investigate the role...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2028. The research project investigates dual-targeting therapeutic approaches for acute myeloid leukemia (AML) by combining BCL-2 (B-cell lymphoma-2) inhibition with CD123-directed natural killer (NK) cell engager immunotherapies. The research...
- Federal Project Grant Summary The National Cancer Institute awarded a $649,293 Project Grant to Ochin, Inc. on September 23, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a longitudinal, multi-level study examining healthcare utilization and outcomes across the cancer care continuum with a focus on social risk factors affecting Latino patients. The research utilizes an electronic health record (EHR)-based dataset from a community health center network...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $168,000 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective July 1, 2025, with completion scheduled for June 30, 2027. The award funds research to examine risk factors and develop predictive models for multiple recurrences of non-muscle invasive bladder cancer (NMIBC). The research leverages existing demographic, lifestyle,...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $807,644 Project Grant on August 13, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and pilot DESCANSO, a culturally adapted cognitive behavioral therapy (CBT) intervention for Spanish-speaking Latino cancer patients. The intervention addresses a symptom cluster of depression, insomnia, and fatigue (DIF) that disproportionately affects Latino cancer patients compared to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $185,760 to the University of Chicago under the Cancer Research Manpower program (CFDA 93.398) on September 15, 2025, for a research project titled "Targeting Glycerol Metabolism in Anti-Tumor Immunity." The award supports a three-year project (concluding August 31, 2028) investigating the mechanistic relationship between glycerol metabolism and CD8+ T cell function in the context of obesity-related...